Addressing food allergies—leading an emerging therapeutic space by responding to a growing and critical unmet medical need

The experienced biotech and pharmaceutical leaders of Aimmune’s executive and management teams are inspired by the patients, families and physicians managing the daily risks associated with food allergies.

Executive Team

Jayson Dallas, MD, is Aimmune’s President and Chief Executive Officer, and a member of Aimmune’s Board of Directors. In more than two decades in the pharmaceutical and biotech industry, Dr. Dallas has successfully overseen multiple product launches, internationally and in the United States, and has led numerous commercial organizations through periods of rapid growth. Prior to joining Aimmune, Dr. Dallas was Ultragenyx Pharmaceutical’s first Chief Commercial Officer, where he oversaw commercial operations, including sales, marketing, reimbursement and new product planning, and led the launches of the company’s first two products. Dr. Dallas also spent five years at Roche as General Manager of Roche in the United Kingdom and as head of global commercial strategy groups at Genentech, focused on oncology, immunology and ophthalmology. Earlier, Dr. Dallas headed the specialty medicines operating unit for Novartis in the United States, after holding several leadership roles of increasing responsibility within the company.
He also held significant medical and marketing positions as he built his career at Pfizer, Roche and Proctor & Gamble Pharmaceuticals. In his career, Dr. Dallas has played important roles in the launch and lifecycle management of numerous drugs, including Crysvita®, Mepsevii®, Herceptin®, Rituxin®, Actemra®, Lucentis®, Exelon® Patch, Trileptal®, Somavert®, Genotropin®, Xenical® and Didronel®. Before joining the pharmaceutical industry, Dr. Dallas practiced medicine in South Africa and in the United Kingdom, and worked as a research physician. Dr. Dallas holds an MD from the University of the Witwatersrand in Johannesburg, South Africa, and an MBA from Ashridge in Berkhamsted, United Kingdom. He is currently a member of the board of directors of Arena Pharmaceuticals, Inc.
Daniel C. Adelman, MD, is Aimmune’s Chief Medical Officer. As an allergist and immunologist, he has led drug development at biotechnology companies for more than 20 years and taught and practiced medicine at the University of California, San Francisco, for more than 25 years. Most recently, Dr. Adelman spent seven years as Chief Medical Officer and Senior Vice President of Development at Alvine Pharmaceuticals, a biopharmaceutical company focused on autoimmune and inflammatory diseases, particularly celiac disease. He held the same positions, as Chief Medical Officer and Senior Vice President of Development, during five years at Sunesis Pharmaceuticals, Inc. Earlier, Dr. Adelman served in various roles at Pharmacyclics, Inc., including Vice President of Clinical Operations and Biometrics, and was a Clinical Scientist at Genentech, Inc.
Dr. Adelman has published extensively in allergy, clinical immunology and autoimmunity, and oncology. He served on the Research Advisory Board of Food Allergy Research & Education (FARE) for more than five years and on the editorial board of the Journal of Allergy and Clinical Immunology for five years. He now serves on several clinical scientific advisory boards and on the editorial boards of Clinical Immunology and Journal of Clinical Immunology. Dr. Adelman holds a bachelor’s degree in biology from the University of California, Berkeley, and earned his MD from the University of California, Davis.
Eric Bjerkholt is Aimmune’s Chief Financial Officer. He has more than three decades of healthcare and biotechnology leadership experience in finance and related functions, both as an executive at publicly traded and early-stage companies and as an investment banker. Prior to joining Aimmune, he was CFO at Sunesis Pharmaceuticals, Inc., where, over 13 years with the company, his role expanded to oversee business development and multiple aspects of governance and corporate relations. In addition to taking Sunesis through its initial public offering in 2005, he raised more than $400 million for the company in other financings.
Prior to Sunesis, Mr. Bjerkholt was CFO at IntraBiotics Pharmaceuticals, Inc., and LifeSpring Nutrition, Inc. He began his healthcare career at J.P. Morgan & Co. as an investment banker in New York and then launched the company’s Western U.S. healthcare practice. Mr. Bjerkholt holds a Cand. Oecon. (master’s) degree in economics from the University of Oslo and an MBA from Harvard Business School. He has served on the boards of directors of several publicly traded companies and is currently a member of the board of directors of Cerus Corporation as well as a member of the board of directors and chair of the audit committee of Corium International, Inc.
Becki Filice is Aimmune’s Senior Vice President of Product and Portfolio Management. She has more than 20 years of healthcare and biotechnology product development experience, and has been involved in numerous product approvals and associated commercialization efforts. Prior to joining Aimmune, Ms. Filice was Global President of Portfolio and Alliance Management at SFJ Pharmaceuticals, where she oversaw project leadership, alliance management, and new portfolio project evaluation. Previously, she was Senior Vice President of Development Operations and Portfolio Management at Achaogen, advancing anti-infectives targeting drug-resistant organisms.
She has also held increasingly senior roles at Genentech, where she spent 15 years in a number of operational and strategic positions. Ms. Filice holds a BA in Microbiology from the University of California, Davis and an MBA from Santa Clara University. She has served on the boards of directors of several non-profit organizations, most recently on the executive committee of the Healthcare Businesswomen’s Association (HBA) San Francisco Bay Area Chapter.
Andrew Oxtoby is Aimmune’s Chief Commercial Officer. He has two decades of experience in the healthcare and consumer products industries, including extensive global pharmaceutical experience with successful product launches, commercialization and strategic planning. Prior to joining Aimmune, Mr. Oxtoby spent 16 years at Eli Lilly and Company, where he most recently had responsibility for Lilly’s U.S. insulin business as Vice President of U.S. Diabetes Connected Care and Insulins, an innovative, patient-focused business unit, after having served as Vice President of U.S. Diabetes Sales.
In his time at Lilly, he also spent five years in oncology, including as Vice President of the International Oncology business; served as General Manager of Lilly’s Netherlands operation; and held positions of increasing responsibility in marketing and sales. Mr. Oxtoby began his career at Procter & Gamble, where he spent four years in the engineering and manufacturing organizations. Mr. Oxtoby holds an MBA from Harvard Business School and a BS in mechanical engineering from Purdue University.
Mary Rozenman, PhD, is Aimmune’s Senior Vice President of Corporate Development and Strategy. Prior to joining Aimmune in 2015, Dr. Rozenman was a Vice President at Longitude Capital, where she focused on mid-stage biotechnology investments and was an observer on Aimmune’s Board of Directors. Dr. Rozenman was previously a Junior Partner at McKinsey & Company and a leader in the Healthcare and Corporate Finance practices. At McKinsey, she advised senior management of leading pharmaceutical companies on a range of strategic and operational issues across marketing, sales, and clinical and corporate development.
She also led McKinsey’s global Biosimilars practice. Dr. Rozenman holds a PhD in Organic Chemistry and Chemical Biology from Harvard University and a BA in Russian Literature and Biochemistry from Columbia University. Her scientific work has been published in premier scientific journals, including Nature, and she is a named inventor on several patents.
Douglas Sheehy is Aimmune’s General Counsel and Secretary. He has more than 20 years of both in-house and law firm experience, including nearly a decade as general counsel. Mr. Sheehy joined Aimmune from Codexis, Inc., a developer of biocatalysts for the pharmaceutical and fine chemical industries, where he was hired as General Counsel and Secretary in 2007. Most recently, he was also the company’s Chief Administrative Officer.
Previously, Mr. Sheehy spent five years in key legal roles at CV Therapeutics, Inc., a publicly held biopharmaceutical company that was subsequently acquired by Gilead in 2009. He began his legal career as a corporate attorney at Gunderson Dettmer LLP. Mr. Sheehy holds a BA in history from Dartmouth College and a JD from American University, where he served as Editor-in-Chief of the Law Review.
Bill Turner is Aimmune’s Senior Vice President, Technical Operations and Regulatory Science. He has more than 25 years of experience in regulatory affairs and quality assurance with biotechnology companies in all stages of clinical development, including extensive experience in biologics. Most recently, he led his own consultancy, where he advised executives and led regulatory and quality activities across multiple therapeutic areas.
Previously, Mr. Turner spent seven years at Dynavax Technologies, where he was Vice President, Regulatory Affairs and Corporate Quality Systems, and six years at MedImmune where he was Senior Director of Regulatory Affairs. Earlier in his career, he handled regulatory affairs at Allergan and Alpha Therapeutics Corporation (now Grifols Biologicals). Mr. Turner holds a BS degree in Medical Microbiology from California State University, Long Beach.